Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...

From ghost postings to AI-powered résumé screening, here's what you need to know about the “wonky,” “brutal” and “weird” ...

Takeda Pharmaceutical Co Ltd (TSE:4502) is set to release its Q4 2024 earnings on May 8, 2025. The consensus estimate for Q4 2024 revenue is $1.07 billion, and the earnings are expected to come in at ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...

Japanese drugmaker Shionogi said on Wednesday that it will acquire Torii Pharmaceutical , a subsidiary of Japan Tobacco , for ...